Ikena Oncology, Inc. has announced that Institutional Shareholder Services Inc. and Glass, Lewis & Co. recommend stockholders vote in favor of the proposed merger with Inmagene Biopharmaceuticals. This merger involves the issuance of shares as outlined in the company's proxy vote proposal. Inmagene, a privately held biopharmaceutical company, is developing IMG-007, an anti-OX40 monoclonal antibody with potential applications in the I&I space. Ikena's CEO, Mark Manfredi, expressed optimism about the merger, citing recent progress in treating patients in a Phase 2B study for atopic dermatitis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492863-en) on July 11, 2025, and is solely responsible for the information contained therein.